Comparative Study Of Sufentanil Self-controlled Analgesic Pump And Oxycodone Hydrochloride Controlled-release Tablets In The Treatment Of Moderate And Severe Cancer Pain

Objective:To observe and compare the efficacy and adverse events of sufentanil self-controlled analgesic pump and oxycodone hydrochloride sustained-release tablets in the treatment of moderate and severe cancer pain.Methods:A total of 52 patients with moderate to severe cancer pain who were hospitalized in the Oncology Department of Jiangxi Provincial People's Hospital from May 2019 to May 2020 were collected and divided into experimental group and control group according to the random number table method.Sufentanil intravenous self-controlled analgesic pump was used to treat moderate to severe cancer pain for 3 consecutive days;the control group was given oral oxycodone for moderate to severe cancer pain for 3 consecutive days.The onset time,pain score,quality of life score,and adverse events were observed and recorded in both groups.Results:1.The analgesic onset time of sufentanil intravenous pump is 31.92±5.19 min,and the analgesic onset time of oxycodone is 74.62±4.11 min,the difference was statistically significant(P<0.05).2.The total pain relief rate of the sufentanil group was 92.31%,of which,the pain relief rate of patients with moderate cancer pain was 100%,and the pain relief rate of severe patients was 83.33%;the total pain relief rate of the oxycodone group was 84.62%,of which the pain relief rate was 100% for moderate patients and 60%for severe patients.There was no statistical difference between the two groups(P>0.05).3.The scores of patients at the time of resting,the scores at the time of activity,and the scores at the most severe time after treatment were significantly lower than those before treatment(P <0.05),but there was no significant difference between thetwo groups(P> 0.05).In addition,sufentanil can achieve smooth analgesic effect even after being successfully converted into oral administration.4.Except that interpersonal communication could not be improved in patients in the sufentanil group,appetite,spirit,sleep and daily life were significantly improved(P <0.05),while the oxycodone group could only improve mental and sleep quality of life indicators.(P <0.05),there was no statistical difference between the two groups(P> 0.05).5.The most common adverse events of the two groups were constipation.Other adverse events such as skin itching,drowsiness,dizziness,and urinary retention were not significantly different(P>0.05).No adverse events such as muscle rigidity,respiratory depression,and bradycardia were observed.Conclusion:Sufentanil self-controlled analgesic pump and oxycodone hydrochloride sustained-release tablets titration can achieve a good pain relief rate for moderate and severe cancer pain,significantly improve the QoL of patients,high safety,most of the adverse events can be improved or tolerated with prolonged medication or symptomatic treatment.But Sufentanil intravenously controlled analgesia has the advantage over oral oxycondone titration in that it is easier to operate and can achieve a better titration effect at a faster rate.Therefore,sufentanil intravenous self-controlled analgesic pump can effectively perform initial dose titration in patients with moderate to severe cancer pain,control burst pain in time,and smoothly switch to oral opioid maintenance after the analgesic effect is stable,which can provide a reference for clinical popularization and application.